非小细胞肺癌（NSCLC）仍然是全球癌症相关死亡的主要原因之一，对全球健康构成严重威胁。粉防己碱 (Tet) 是一种中药小分子，已被证明对多种癌症具有主要功效。尽管之前的研究已经证明Tet对NSCLC具有潜在的抗癌作用，但其较差的水溶性限制了其进一步的临床应用。在此，提出了一种基于纳米颗粒的新型药物递送系统，即血小板膜（PLTM）涂覆的Tet负载的聚己内酯-b-聚（乙二醇）-b-聚己内酯纳米颗粒（PTeNPs），以增加Tet对抗NSCLC的效力。首先，采用乳液溶剂蒸发法制备汉防己碱纳米粒子（TeNPs），并通过用PLTM涂覆纳米粒子来制备仿生纳米粒子（PTeNPs）。当涂有 PLTM 时，PTeNP 被巨噬细胞吞噬的程度比 Tet 和 TeNP 少得多。此外，与Tet和TeNPs相比，PTeNPs在体外和体内均能显着抑制NSCLC的生长和侵袭。该药物递送系统具有可靠的生物安全性，为NSCLC提供了一种缓释和高效抗癌作用的新方法，促进了Tet与现代纳米技术的结合。

Nonsmall cell lung cancer (NSCLC) remains one of the leading causes of cancer-related death worldwide, posing a serious threat to global health. Tetrandrine (Tet) is a small molecule in traditional Chinese medicine with proven primary efficacy against multiple cancers. Although previous studies have demonstrated the potential anticancer effects of Tet on NSCLC, its poor water solubility has limited its further clinical application. Herein, a novel nanoparticle-based drug delivery system, platelet membrane (PLTM)-coated Tet-loaded polycaprolactone-b-poly(ethylene glycol)-b-polycaprolactone nanoparticles (PTeNPs), is proposed to increase the potency of Tet against NSCLC. First, tetrandrine nanoparticles (TeNPs) are created using an emulsion solvent evaporation method, and biomimetic nanoparticles (PTeNPs) are prepared by coating the nanoparticles with PLTMs. When coated with PLTMs, PTeNPs are considerably less phagocytized by macrophages than Tet and TeNPs. In addition, compared with Tet and TeNPs, PTeNPs can significantly inhibit the growth and invasion of NSCLC both in vitro and in vivo. With reliable biosafety, this drug delivery system provides a new method of sustained release and efficient anticancer effects against NSCLC, facilitating the incorporation of Tet in modern nanotechnology.